TY - JOUR
T1 - GD2 and GD3 gangliosides as prognostic biomarkers in high grade serous ovarian cancer
AU - Levin, Gabriel
AU - Matanes, Emad
AU - Yasmeen, Amber
AU - Meyer, Raanan
AU - Brodeur, Melica Nourmoussavi
AU - Salvador, Shannon
AU - Lau, Susie
AU - Saragovi, H. Uri
AU - Gotlieb, Walter
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2025/1
Y1 - 2025/1
N2 - Objective: Gangliosides GD2 and GD3 have been proposed to be of significance in diagnosis of ovarian masses. We aim to study serum GD2 and GD3 gangliosides as predictors of oncological outcomes among high grade serous (HGS) ovarian cancer (OC). Materials and methods: A retrospective study including biobanked serum samples of HGS OC treated between 2005 and 2016. Serum GD2 and GD3 concentrations were quantified using indirect ELISA and analyzed with respect to survival. Results: Sixty patients were included. Patients with GD3>12.8 ng/mL had shorter PFS when compared to patients with lower level; median 31 vs. 67 months, p = 0.005. Patients with GD2> 7.1 ng/mL had shorter median PFS than those with lower level of (23 vs. 52 months, p = 0.024.) Patients with GD3>14.5 ng/mL had shorter OS vs. patients with lower level (median 31 vs. 70 months, p = 0.002). In a Cox regression, following adjustment for age, CA-125, disease stage and age, serum elevated GD3 was independently associated with short PFS (adjusted hazard ratio 2.0, 95 % CI 1.1–3.8, p=.024). In a separate Cox regression, elevated GD2 was independently associated with PFS (adjusted hazard ratio3.0 (1.2–7.7). p=.019. High serum GD3 and GD2 were independently associated with short OS as well. Conclusions: High levels of serum GD2 and GD3 in HGS OC were associated with shorter PFS and OS. GD3 is superior to GD2 as a biomarker for prognosis.
AB - Objective: Gangliosides GD2 and GD3 have been proposed to be of significance in diagnosis of ovarian masses. We aim to study serum GD2 and GD3 gangliosides as predictors of oncological outcomes among high grade serous (HGS) ovarian cancer (OC). Materials and methods: A retrospective study including biobanked serum samples of HGS OC treated between 2005 and 2016. Serum GD2 and GD3 concentrations were quantified using indirect ELISA and analyzed with respect to survival. Results: Sixty patients were included. Patients with GD3>12.8 ng/mL had shorter PFS when compared to patients with lower level; median 31 vs. 67 months, p = 0.005. Patients with GD2> 7.1 ng/mL had shorter median PFS than those with lower level of (23 vs. 52 months, p = 0.024.) Patients with GD3>14.5 ng/mL had shorter OS vs. patients with lower level (median 31 vs. 70 months, p = 0.002). In a Cox regression, following adjustment for age, CA-125, disease stage and age, serum elevated GD3 was independently associated with short PFS (adjusted hazard ratio 2.0, 95 % CI 1.1–3.8, p=.024). In a separate Cox regression, elevated GD2 was independently associated with PFS (adjusted hazard ratio3.0 (1.2–7.7). p=.019. High serum GD3 and GD2 were independently associated with short OS as well. Conclusions: High levels of serum GD2 and GD3 in HGS OC were associated with shorter PFS and OS. GD3 is superior to GD2 as a biomarker for prognosis.
KW - Biomarker
KW - Diagnostic test
KW - Elisa
KW - Ganglioside
KW - Liquid biopsy
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=85205777041&partnerID=8YFLogxK
U2 - 10.1016/j.jogoh.2024.102860
DO - 10.1016/j.jogoh.2024.102860
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 39366506
AN - SCOPUS:85205777041
SN - 0368-2315
VL - 54
JO - Journal of Gynecology Obstetrics and Human Reproduction
JF - Journal of Gynecology Obstetrics and Human Reproduction
IS - 1
M1 - 102860
ER -